Molina Healthcare Profit Slides Amid Membership Contraction

The company’s bottom line took a hit as premium revenue declined by 6%, a trend management attributed to shrinking enrollment numbers. Despite the earnings slump, the firm’s adjusted earnings per share of $1.51 managed to edge past the $1.39 consensus estimate from FactSet analysts. Chief Executive Joseph Zubretsky noted that the misalignment between Medicaid reimbursement rates and actual medical expenses has started to stabilize. He anticipates 2026 will serve as a low point for Medicaid margins, clearing a path for a return to profitable growth by 2027.

Looking ahead, Molina raised its fiscal 2026 outlook, projecting adjusted earnings of at least $5.25 per share. This forecast accounts for specific headwinds, including a $1.50 per share loss tied to a new Florida Medicaid contract and a $1.00 per share drag from its traditional Medicare Advantage Prescription Drug (MAPD) product. The company plans to exit the MAPD market entirely by 2027 to focus on more stable segments of its portfolio.